EUCTR2007-005129-31-IT进行中（未招募）1 期
A randomized, controlled, open-label, multi-centre, parallel-group study to assess all-cause mortality and cardiovascular morbidity in patients with chronic kidney disease on dialysis and those not on renal replacement therapy under treatment with MIRCERA or reference ESAs. - ND
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- ROCHE
- 入组人数
- 2,800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written informed consent 2. Adult patients (>= 18 years old) with symptomatic anemia associated with CKD (renal anemia) 3. Patients with renal anemia who are not treated with an ESA: ? Anemia defined as Hb concentration < 11.0 g/dL (mean of 2 screening values with at least one day and a maximum 2 weeks between measurements) with a clinical indication for ESA treatment or 3. Patients with renal anemia who are on maintenance ESA therapy: ? If on dialysis: regular long-term hemodialysis or peritoneal dialysis therapy with the same mode of dialysis for at least 3 months before screening ? Continuous iv or sc maintenance ESA therapy: darbepoetin alfa (Aranesp, Nespo, Aranest), epoetin alfa (Eprex, Epogen, Epopen, Erypo) or epoetin beta (NeoRecormon, Recormon) administered according to approved label of the same agent and route of administration for at least 2 months before screening ? Hb concentration between 10 and 12 g/dL (mean of 2 screening values with at least one day and a maximum of 2 weeks between measurements) 4. Patients with adequate iron status defined as: serum ferritin above or equal to 100 μg/L or transferrin saturation above or equal to 20% (See section 4.4 of the SmPC).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Contraindications to ESA treatment (See Section 4.3 of SmPC): 1. Uncontrolled hypertension 2. Hypersensitivity to the active substance or any of the excipients of MIRCERA and other ESAs 3. Any other contraindication to ESA therapy Conditions known to cause inadequate response to ESA treatment or anemia other than symptomatic anemia associated with CKD, including (See Section 4.4. of the SmPC): 4. Hemoglobinopathies (e.g., homozygous sickle-cell disease, thalassemia of all types) 5. Anemia due to hemolysis 6. Pure red cell aplasia (PRCA) Other 7. High likelihood of early withdrawal (e.g. within 1 year) or interruption of the study 8. Pregnancy or breast-feeding 9. Women of childbearing potential without effective contraception 10. Administration of another investigational drug within 1 month before screening or planned during the study period
研究者
相似试验
进行中（未招募）
1 期
A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.EUCTR2007-005129-31-CZF.Hoffmann-La Roche Ltd2,800
进行中（未招募）
1 期
A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.To gain more experience with MIRCERA administered under clinical practice conditions and according to the approved label by performing a non-inferiority study comparing MIRCERA to other ESAs in terms of cardiovascular morbidity and mortality.MedDRA version: 14.1 Level: PT Classification code 10058116 Term: Nephrogenic anaemia System Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2007-005129-31-GBF.Hoffmann-La Roche Ltd2,825
进行中（未招募）
1 期
A randomized, controlled, open-label, multi-centre, parallel-group study to assess all-cause mortality and cardiovascular morbidity in patients with chronic kidney disease on dialysis and those not on renal replacement therapy under treatment with MIRCERA® or reference ESAs. - Post Authorization Safety Study (PASS)To gain more experience with MIRCERA administered under clinical practice conditions and according to the approved label by performing a non-inferiority study comparing MIRCERA to other ESAs in terms of cardiovascular morbidity and mortality.MedDRA version: 9.1Level: PTClassification code 10058116Term: Nephrogenic anaemiaEUCTR2007-005129-31-FRF.Hoffmann-La Roche Ltd2,800
进行中（未招募）
1 期
A randomized, controlled, open-label, multi-centre, parallel-group study to assess all-cause mortality and cardiovascular morbidity in patients with chronic kidney disease on dialysis and those not on renal replacement therapy under treatment with MIRCERA® or reference ESAs. - Post Authorization Safety Study (PASS)To gain more experience with MIRCERA administered under clinical practice conditions and according to the approved label by performing a non-inferiority study comparing MIRCERA to other ESAs in terms of cardiovascular morbidity and mortality.MedDRA version: 9.1Level: PTClassification code 10058116Term: Nephrogenic anaemiaEUCTR2007-005129-31-GRF. Hoffmann-La Roche Ltd2,800
进行中（未招募）
1 期
A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.EUCTR2007-005129-31-SEF.Hoffmann-La Roche Ltd2,800